In line with the limited amount of in vivo studies, to date also no clinical studies have been conducted on the potential therapeutic options of EPHB2 and its EphrinB ligands in inflammation, immunity, or atherosclerosis. The gene discussed is EPHB2; the disease is atherosclerosis.